Showing results (411-420 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|October 12, 2016
Estimates of the direct and indirect cost savings associated with heart disease that could be avoided through dietary change in the United StatesJohn Cawley, Chad Meyerhoefer, Leah G Gillingham, et al.Journal of Medical Economics|April 30, 2014
A cost-analysis model for anticoagulant treatment in the hospital settingSamir H Mody, Lynn Huynh, Daisy Y Zhuo, et al.Journal of Medical Economics|March 12, 2014
Is transcatheter aortic valve implantation (TAVI) a cost-effective treatment in patients who are ineligible for surgical aortic valve replacement? A systematic review of economic evaluationsJames Eaton, Stuart Mealing, Juliette Thompson, et al.Journal of Medical Economics|February 26, 2014
Cost-effectiveness of asenapine in the treatment of schizophrenia in CanadaJean Lachaine, Catherine Beauchemin, Karine Mathurin, et al.Journal of Medical Economics|October 6, 2016
Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in JapanYasuo Yanagi, Aya Fukuda, Victor Barzey, et al.Journal of Medical Economics|April 12, 2014
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodesLaura Sawyer, Jean-Michel Azorin, Stacey Chang, et al.Journal of Medical Economics|April 12, 2014
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomSimon Rule, Graham P Collins, Kunal SamantaJournal of Medical Economics|November 1, 2018
Impact of treatment with liposomal bupivacaine on hospital costs, length of stay, and discharge status in patients undergoing total knee arthroplasty at high-use institutionsCarl V Asche, Simon Dagenais, Amiee Kang, et al.Journal of Medical Economics|April 19, 2017
Global health resource utilization associated with pacemaker complicationsCatherine Waweru, Anna Steenrod, Claudia Wolff, et al.Journal of Medical Economics|March 22, 2019
Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiariesAntoine Lafuma, François-Emery Cotté, Christophe Le Tourneau, et al.Pageof 241